The AHA Aug. 28 urged the Drug Enforcement Administration to reconsider its proposed 2019 aggregate production quotas for certain controlled substances, which the agency said would reduce manufacturing quotas for six frequently misused opioids by an average 10 percent. “Hospitals and other providers are currently facing critical shortages of a number of injectable opioid medications for which that the DEA recommends quota reductions, including morphine, hydromorphone, and fentanyl,” AHA said in a letter to DEA. “These decreases would exacerbate these already dire shortages.” AHA said its request is “specific to these injectable medopications and does not extend to other dosage forms or opioid products.” Comments are due Sept. 19.